

## Metastasis to the Thyroid Gland: A Critical Review

Iain J. Nixon, MBChB, PhD<sup>1</sup>, Andrés Coca-Pelaz, MD, PhD<sup>2</sup>, Anna I. Kaleva, MBChB, MRCS-ENT<sup>3</sup>, Asterios Triantafyllou, PhD, FRCPATH<sup>4,5</sup>, Peter Angelos, MD, PhD, FACS<sup>6</sup>, Randall P. Owen, MD, FACS<sup>7</sup>, Alessandra Rinaldo, MD, FRCSEd ad hominem, FRCS (Eng, Ir) ad eundem, FRCSGlasg, FACS<sup>8</sup>, Ashok R. Shaha, MD<sup>9</sup>, Carl E. Silver, MD, FACS<sup>10</sup>, and Alfio Ferlito, MD, DLO, DPath, FRCSEd ad hominem, FRCS (Eng, Glasg, Ir) ad eundem, FDSRCS ad eundem, FACS, FHKCORL, FRCPATH, FASCP, IFCAP<sup>11</sup>

<sup>1</sup>ENT Department, NHS Lothian, Edinburgh, UK; <sup>2</sup>Department of Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain; <sup>3</sup>ENT Department, East and North Hertfordshire Trust, Stevenage, UK; <sup>4</sup>Oral and Maxillofacial Pathology, School of Dentistry, University of Liverpool, Liverpool, UK; <sup>5</sup>Department of Cellular Pathology, Liverpool Clinical Laboratories, Liverpool, UK; <sup>6</sup>Department of Surgery and MacLean Center for Clinical Ethics, The University of Chicago Medicine, Chicago, IL; <sup>7</sup>Division of Surgical Oncology, Department of Surgery, Mount Sinai School of Medicine, New York, NY; <sup>8</sup>University of Udine, Udine, Italy; <sup>9</sup>Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>10</sup> Department of Surgery, University of Arizona College of Medicine—Phoenix, Phoenix, AZ; <sup>11</sup>International Head and Neck Scientific Group, Padua, Italy

### ABSTRACT

**Background.** Metastasis to the thyroid gland from non-thyroid sites is an uncommon clinical presentation in surgical practice. The aim of this review was to assess its incidence management and outcomes.

**Methods.** A literature review was performed to identify reports of metastases to the thyroid gland. Both clinical and autopsy series were included.

**Results.** Metastases to the gland may be discovered at the time of diagnosis of the primary tumor, after preoperative investigation of a neck mass, or on histologic examination of a thyroidectomy specimen. The most common primary tumors in autopsy studies are from the lung. In clinical series, renal cell carcinoma is most common. For patients with widespread metastases in the setting of an aggressive malignancy, surgery is rarely indicated. However, when patients present with an isolated metastasis diagnosed during follow-up of indolent disease, surgery may achieve

control of the central neck and even long-term cure. Other prognosticators include features of the primary tumor, time interval between initial diagnosis and metastasis, and extrathyroid extent of disease.

**Conclusions.** In patients with thyroid metastases, communication among clinicians treating the thyroid and the index primary tumor is essential. The setting is complex, and decisions must be made considering the features of the primary tumor, overall burden of metastases, and comorbidities. Careful balancing of these factors influences individualized approaches.

The earliest description of metastasis to thyroid gland is attributed to Virchow, who described a testicular tumor metastasis in 1871. Given the extensive blood supply to the gland, the low incidence of metastases to the thyroid is surprising<sup>1</sup>. Willis suggested that this is influenced by the glandular microenvironment; the fast arterial blood flow and high concentration of oxygen and iodine could thus prevent the anchorage and secondary growth of circulating tumor cells.<sup>1</sup>

While postmortem examination suggests that as many as 24% of patients who die of nonthyroid malignancies have metastases to this gland, these seem rare in clinical practice.<sup>2–4</sup> Although the majority (60–80%) of patients who present with thyroid metastasis are diagnosed in the setting of known previous malignancy, an occult primary tumor accounts for a significant percentage (20–40%).<sup>4,5</sup> In

---

This article was written by members and invitees of the International Head and Neck Scientific Group ([www.IHNSG.com](http://www.IHNSG.com)).

---

© The Author(s) 2016. This article is published with open access at Springerlink.com

First Received: 25 August 2016;  
Published Online: 21 November 2016

I. J. Nixon, MBChB, PhD  
e-mail: [iainjnxon@nhs.net](mailto:iainjnxon@nhs.net)

addition, some patients are diagnosed during preoperative investigation, while others will be diagnosed on histologic examination of a thyroidectomy specimen.

### PRIMARY ORIGIN OF THYROID METASTASES

In autopsy series, the incidence of metastases overall is 2%. In autopsy series, the most common site of primary tumor is the lung, whereas in clinical series renal cell carcinoma (RCC) is more common (Table 1).<sup>1,6–18</sup> Because of the aggressive nature of lung malignancies, patients are often treated with palliative intent from an early stage, and investigation for additional metastases is therefore curtailed. In contrast, RCC is less aggressive, and patients are more likely to be further investigated and treated for metastatic disease. Metastasis to the thyroid should not be confused with direct infiltration of the thyroid by locally aggressive disease in the larynx or upper esophagus, as reported in some series.<sup>19</sup> Metastases can originate at almost any primary site<sup>20–27</sup> Figure 1 summarizes the most common primary tumors reported in clinical series to metastasize to the thyroid (Table 2).<sup>21,26,28–51</sup>

### PREOPERATIVE INVESTIGATION

An accurate clinical history is significant. A prior malignancy, as well as symptoms such as hematuria or hemoptysis, may raise the possibility of an occult primary tumor in the kidneys or lungs. However, many patients with thyroid metastasis present with signs and symptoms


identical to those with primary thyroid disease. One study indicates that 72% present with a palpable neck mass and 28% with an incidental lesion identified on imaging.<sup>52</sup> Thyroid metastasis at an advanced stage within the central neck may result in dysphagia and dysphonia, similar to aggressive thyroid malignancy. Changes in thyroid function are late and relatively uncommon.<sup>5,53</sup>

The accuracy of thyroid imaging has improved with the introduction of high-resolution ultrasound as well as cross-sectional [computed tomography/magnetic resonance imaging (CT/MRI)] and functional imaging [positron emission tomography (PET)]. Nevertheless, even sophisticated techniques cannot reliably differentiate between primary thyroid lesions and metastases.<sup>28,54</sup> Fine needle aspiration cytology (FNAC) can often be of assistance.<sup>55,56</sup> In the setting of metastatic lesions to the thyroid, FNAC positive and negative predictive values of 89 and 93%, respectively, have been reported, and application of molecular markers (e.g., the *BRAF* growth promoter in papillary thyroid cancer) and immunohistochemistry may be of further help (e.g., CD-10 in RCC).<sup>25,57–59</sup> There limitations of cytology are acknowledged.<sup>29,56,60</sup> Poorly differentiated tumors such as aggressive anaplastic thyroid cancers can be difficult to differentiate from high grade metastases.<sup>54,58,61,62</sup> In addition, neck hematoma after needle biopsy of RCC has anecdotally been seen and should raise concerns for performing core biopsies of lesions suspicious for RCC. Rare, and hence morphologically unfamiliar, tumors and lack of cellular differentiation and expression of antigens conveniently detected by

**TABLE 1** Frequency of metastasis to the thyroid gland in autopsy series

Study	No. thyroid metastases/no. of autopsies	%	Most frequent site of primary tumor
Müller <sup>8</sup>	11/623	1.8	Not available
Symmers <sup>9</sup>	7/298	2.3	Not available
Kitain <sup>10</sup>	14/452	3.1	Not available
Willis <sup>1</sup>	9/170	5.2	Breast
Rice <sup>11</sup>	9/89	10.1	Not available
Abrahms et al. <sup>12</sup>	19/1000	1.9	Breast
Thorpe <sup>13</sup>	4/200	2	Not available
Hull <sup>14</sup>	10/59	16.9	Lymphoid tissue
Mortensen et al. <sup>15</sup>	18/467	3.9	Lymphoid tissue
Shimaoka et al. <sup>7</sup>	188/1980	9.5	Breast
Brierre and Dickinson <sup>16</sup>	14/53	26.4	Not available
Silverberg and Vidone <sup>77</sup>	15/62	24.2	Lung
Berge and Lundberg <sup>51</sup>	201/16294	1.25	Breast
Watanabe and Tsuchiya <sup>18</sup>	4/309	1.29	Lung
Moghaddam et al. <sup>6</sup>	4/2117	0.46	Lung
Total (mean)	527/24173	2	Lung

**FIG. 1** Total number of cases of metastasis to thyroid reported in literature stratified by site of primary tumor



**TABLE 2** Incidence of primary tumors metastasising to the thyroid and treatment as reported in clinical series

Study	<i>n</i>	Most frequent site of primary tumor	Total thyroidectomy (%)
Mayo et al. <sup>42</sup>	19	Lung	Not available
Elliot et al. <sup>34</sup>	14	Breast = lung	43
Wychulis et al. <sup>43</sup>	14	Kidney	14
Harcourt-Webster <sup>35</sup>	11	Skin	0
Pillay et al. <sup>44</sup>	10	Esophagus	10
Brady et al. <sup>36</sup>	14	Lung	Not available
Ericsson et al. <sup>33</sup>	10	Kidney	70
Czech et al. <sup>32</sup>	12	Kidney	100
Ivy et al. <sup>37</sup>	30	Kidney	Not available
Chacho et al. <sup>45</sup>	8	Blood	0
Smith et al. <sup>46</sup>	19	Breast	0
Michelow et al. <sup>47</sup>	21	Lung	0
Rosen et al. <sup>21</sup>	11	Lung	55
Nakhjavani et al. <sup>28</sup>	43	Kidney	21
Lam et al. <sup>38</sup>	79	Lung	Not available
Chen et al. <sup>40</sup>	10	Kidney	50
De Ridder et al. <sup>26</sup>	6	Kidney	67
Dequanter et al. <sup>48</sup>	11	Lung	82
Wood et al. <sup>30</sup>	15	Kidney	47
Kim et al. <sup>29</sup>	22	Breast	9
Mirallié et al. <sup>49</sup>	29	Kidney	72
Cichoń et al. <sup>31</sup>	17	Kidney	94
Gerges et al. <sup>39</sup>	7	Lung	0
Choi et al. <sup>50</sup>	46	Lung	0
Russell et al. <sup>41</sup>	17	Kidney	65

immunohistochemistry account for some of the difficulties.<sup>2,61</sup> To increase the likelihood of a preoperative diagnosis, more invasive investigations such as core or open biopsy have been considered.<sup>4,30</sup> Obviously, the multidisciplinary team must have a high index of suspicion, particularly in patients with a history of malignancy.

## AIMS OF TREATMENT

Many patients who present with a thyroid metastasis will be treated with palliative intent. For selected patients, however, lobectomy or total thyroidectomy may be performed, either with the aim of long-term cure or achieving local control.<sup>31</sup> A balance must be reached regarding the course of systemic disease versus the likely outcome from uncontrolled local disease. Because of the nature of reported surgical series, the percentage of patients who present with metastasis to the thyroid who are considered candidates for surgery is unclear. Local invasion of thyroid disease, irrespective of the source of malignancy, results in dysphonia, dysphagia, hemoptysis, and stridor. Unfortunately, few data exist on the frequency of presenting symptoms. In addition, the patient's fitness and comorbidities need to be weighed against the likelihood of surgical success. The necessary close communication between the teams involved in the management of primary disease and thyroid is ensured by modern multidisciplinary team management.

If the metastasis is confined within the thyroid gland without evidence of significant extraglandular extension, thyroidectomy may be performed with minimal morbidity. In appropriately selected cases, the aim would be to prevent asphyxia and hemoptysis associated with uncontrolled disease in the central neck.<sup>32,33</sup>

In the case of a relatively indolent primary malignancy present with an isolated thyroid metastasis presenting many years after treatment for the index tumor, surgery with curative intent is possible. Continuous communication between the management teams positively influences patient counseling and treatment planning.

## PROGNOSTIC FACTORS

Although distant metastases are often an adverse prognosticator, thyroid metastases may not have as poor an outcome as those elsewhere.<sup>52</sup> Nevertheless, 35 to 80% of patients with thyroid involvement present with multiorgan metastases.<sup>5,52,63</sup>

Overall prognosis appears to be most closely linked to the innate features of the primary tumor.<sup>5</sup> As already noted, if the primary tumor is amenable to treatment with curative intent, the subgroup of patients with isolated thyroid metastasis would be candidates for curative treatment of

the metastasis as well.<sup>19,64</sup> When considering thyroid surgery in a palliative setting, the thyroid team should consider the burden/volume of metastatic disease elsewhere and the effect of extrathyroidal extension on surgical morbidity, but individualized decisions are complex.<sup>65</sup>

For those patients with an indolent primary lesion and disease confined to the thyroid gland without significant extrathyroid extension, outcomes may be favorable. In contrast, patients with aggressive primary disease, multiorgan metastases, and invasive thyroid metastases will fare less well.

Mean survival after surgery for thyroid metastasis is approximately 2 years, with 42% 5-year overall survival.<sup>4,63</sup> However, in the majority of those patients who are selected for thyroid metastasectomy, long-term control of the central neck can be achieved.

In the case of RCC, approximately 20% of these patients are diagnosed with distant metastases at the time of diagnosis. Another 30% will go on to develop metastases during follow-up, and some of these may present after a significant delay of up to 20 years.<sup>66–68</sup> Overall prognosis for these patients is poor, but thyroid metastasectomy for selected patients may offer good survival rates (30–50%), and long disease-free intervals are reported.<sup>69</sup> Hence, the European Association of Urology guidelines support treatment of thyroid metastases with surgery.<sup>70</sup>

Of the lung tumors known to metastasize to the thyroid, non-small cell lung cancer is the most common type.<sup>71</sup> With regard to breast cancer, 5 to 10% of cases present with distant metastases at the time of diagnosis, and occasionally these are in the thyroid.<sup>72,73</sup> Evidence relating to the management of thyroid metastases in cases of lung and breast cancer is limited, though outcomes appear poor.<sup>6,19,21,28,30–32,34–39,65</sup>

Colorectal cancer has also been reported to be associated with a low incidence of thyroid metastases. One meta-analysis identified 31 cases of thyroid metastases reported between 1954 and 2006.<sup>74</sup> These were usually accompanied with multiorgan distant metastases, and hence, prognosis was poor, with only a 50% survival at 1 year.<sup>74</sup> Treatment for these patients was most commonly thyroidectomy with adjuvant chemotherapy, radiotherapy, or both.<sup>60</sup> The limited evidence available suggests that despite being palliative, thyroidectomy in this setting was associated with reduced morbidity from thyroid-associated respiratory symptoms.<sup>74</sup> Melanoma has been associated with thyroid metastases, and autopsy studies report an incidence of up to 39%.<sup>5,7</sup> Shimaoka et al. analyzed 2050 consecutive autopsy reports between 1955 and 1960. Sixteen (39%) of 41 patients who died of malignant melanoma had metastatic deposits in the thyroid gland.<sup>7</sup> It is possible that as therapy has improved for this disease, rates may currently be lower. As is the case for other primary lesions,

the literature mainly consists of case reports and case series. Hence the management and likelihood of success are undetermined. Additional case reports include small cell lung cancers, pancreatic malignancies, and sarcomas.<sup>21,28,39,40,71</sup> The majority of these presented with multiple metastases against a background of aggressive disease, and as such are inappropriate for thyroid surgery.

In summary, the literature lacks prospective randomized trial evidence, and this is unlikely to ever be available. Prognosis largely depends on the features of the primary malignancy and the metastatic profile at the time of diagnosis—that is, timing, number, and location of metastases.

## SURGICAL STRATEGY

A recent meta-analysis has suggested that those patients managed with surgery experience better outcomes than those managed expectantly.<sup>41</sup> This was most apparent for RCC, where median survival for those managed expectantly was 6 months versus 27 months for those who underwent surgery. However, it is likely that studies included in this were subject to significant bias, with an expectant approach favored in patients with more aggressive disease.

For those patients considered to be candidates for surgery, when considering the extent of thyroidectomy, the aim should be to ensure removal of all gross disease with an adequate margin. The procedure will therefore depend on the extent of disease. In unilateral disease, most authors recommend thyroid lobectomy rather than total thyroidectomy in order to minimize risk to the contralateral recurrent laryngeal nerve and parathyroid glands (Table 2). However, some authors suggest that lobectomy can be associated with positive margins and therefore favor total thyroidectomy.<sup>65</sup> Russell et al. recently demonstrated a decrease in recurrence for patients managed with total thyroidectomy versus thyroid lobectomy (13 vs. 5%,  $p < 0.005$ ), although studies included in this meta-analysis are likely to have been subject to some selection bias.<sup>41</sup> In contrast to primary thyroid malignancy, metastases to the gland are not sensitive to radioactive iodine; therefore, total thyroidectomy is not mandatory as long as adequate margins are achieved. However, patients with multifocal disease may require primary total thyroidectomy.<sup>3,5</sup> When Russell et al. reported their own institutional experience of 17 patients with metastases to the thyroid, 4 (24%) had bilateral disease.<sup>41</sup> In the rare instance that multifocal disease is identified after initial thyroid lobectomy, consideration may be given to completion thyroidectomy.

Concomitant regional lymph node involvement is rare in cases of metastasis to the thyroid; therefore, prophylactic neck dissection is not recommended.<sup>58,60,65,75</sup> However,

the regional lymphatics should be fully assessed preoperatively, particularly in RCC.<sup>68</sup> RCC shows a tendency toward vascular invasion, and involvement of the internal jugular vein has been described both from nodal metastases to the lymph nodes of the neck and from metastases to the thyroid gland.<sup>65</sup> For this reason, contrast-enhanced imaging of the large vessels of the neck should be considered to assess the relationship between disease and vasculature before surgery.

Currently there is no evidence to support any other adjuvant or alternative treatment to surgery.<sup>65</sup> This is partly because the most common primary tumor is RCC, which is largely considered to be resistant to radiotherapy.<sup>76</sup>

## SUMMARY

Autopsy and clinical series provide relevant data. Non-thyroid metastases to the thyroid gland are rare in the clinical setting, with the most common primary tumor being RCC. In autopsy series, the most common primary tumor is lung cancer. Thyroid involvement may be identified during initial staging, at follow-up imaging, or as a new presentation of a neck mass. Preoperative evaluation is similar to that for thyroid primary disease. Awareness of previous malignancy is of significance and would be particularly helpful while assessing FNAC or core/open biopsies. Prognosis will depend on the biology of the primary tumor, the burden/volume of metastases, the course of disease, and any comorbidities. Communication between oncologic teams is essential and influences decision making. In patients selected for surgery, thyroid lobectomy with adequate margins may achieve control of the central neck, whereas total thyroidectomy should be reserved for large-volume or multifocal disease.

**DISCLOSURE** The authors declare no conflict of interest.

**OPEN ACCESS** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## REFERENCES

1. Willis RA. Metastatic tumours in the thyroid gland. *Am J Pathol.* 1931;7:187–208.3.
2. Cordes M, Kuwert T. Metastases of non-thyroidal tumors to the thyroid gland: a regional survey in Middle Franconia. *Exp Clin Endocrinol Diabetes.* 2014;122:273–6.
3. Stevens TM, Richards AT, Bewtra C, Sharma P. Tumors metastatic to thyroid neoplasms: a case report and review of the literature. *Patholog Res Int.* 2011;2011:238693.

4. Nixon IJ, Whitcher M, Glick J, et al. Surgical management of metastases to the thyroid gland. *Ann Surg Oncol*. 2011;18:800–4.
5. Chung AY, Tran TB, Brumund KT, Weisman RA, Bouvet M. Metastases to the thyroid: a review of the literature from the last decade. *Thyroid*. 2012;22:258–68.
6. Moghaddam PA, Cornejo KM, Khan A. Metastatic carcinoma to the thyroid gland: a single institution 20-year experience and review of the literature. *Endocr Pathol*. 2013;24:116–24.
7. Shimaoka K, Sokal JE, Pickren JW. Metastatic neoplasms in the thyroid gland. Pathological and clinical findings. *Cancer*. 1962;15:557–65.
8. Muller M. Beitrag zur Kenntnis der Metastasenbildung maligner Tumoren, nach statistischen Zusammenstellungen aus den Sektionsprotokollen des Bernischen pathologischen Instituts. Bern, Switzerland: L. Scheim & Co.; 1892.
9. Symmers D. Metastasis of tumors; study of 298 cases of malignant growth exhibited among 5155 autopsies at Bellevue Hospital. *Am J Med Sci*. 1917;154:225.
10. Kitain H. Zur Kenntnis der Häufigkeit und der Lokalisation von Krebsmetastasen mit besonderer Berücksichtigung ihres histologischen Baus. *Virchows Arch Path Anat*. 1922;238:289–309.
11. Rice CO. Microscopic metastases in the thyroid gland. *Am J Pathol*. 1934;10:407–12.1.
12. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. *Cancer*. 1950;3:74–85.
13. Thorpe JD. Metastatic cancer in the thyroid gland; report of four cases. *West J Surg Obstet Gynecol*. 1954;62:574–6.
14. Hull OH. Critical analysis of two hundred twenty-one thyroid glands; study of thyroid glands obtained at necropsy in Colorado. *AMA Arch Pathol*. 1955;59:291–311.
15. Mortensen J, Woolner LB, Bennett WA. Secondary malignant tumors of the thyroid gland. *Cancer*. 1956;9:306–9.
16. Briere JT Jr, Dickson LG. Clinically unsuspected thyroid disease. *GP*. 1964;30:94–8.
17. Silverberg SG, Vidone RA. Metastatic tumors in the thyroid. *Pacific Med Surg*. 1966;74:175–80.
18. Watanabe I, Tsuchiya A. Secondary carcinoma of the thyroid gland. *Jpn J Surg*. 1980;10:130–6.
19. McCabe DP, Farrar WB, Petkov TM, Finkelmeier W, O'Dwyer P, James A. Clinical and pathologic correlations in disease metastatic to the thyroid gland. *Am J Surg*. 1985;150:519–23.
20. Chiumento C, Fiorentino A, Castaldo G, Fusco V. A case of thyroid metastasis of nasopharyngeal cancer. *Tumori*. 2011;97:24e–6e.
21. Rosen IB, Walfish PG, Bain J, Bedard YC. Secondary malignancy of the thyroid gland and its management. *Ann Surg Oncol*. 1995;2:252–6.
22. Bae WK, Shim HJ, Choi YD, et al. Severe hypothyroidism induced by thyroid metastasis of cholangiocarcinoma. *Cancer Res Treat*. 2009;41:56–8.
23. Basu S, Alavi A. Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging. *Clin Nucl Med*. 2007;32:388–9.
24. Delitala AP, Vidili G, Manca A, Dial U, Delitala G, Fanciulli G. A case of thyroid metastasis from pancreatic cancer: case report and literature review. *BMC Endocr Disord*. 2014;14:6.
25. Gherardi G, Scherini P, Ambrosi S. Occult thyroid metastasis from untreated uveal melanoma. *Arch Ophthalmol*. 1985;103:689–91.
26. De Ridder M, Sermeus AB, Urbain D, Storme GA. Metastases to the thyroid gland—a report of six cases. *Eur J Intern Med*. 2003;14:377–9.
27. Demir L, Erten C, Somali I, et al. Metastases of renal cell carcinoma to the larynx and thyroid: two case reports on metastasis developing years after nephrectomy. *Can Urol Assoc J*. 2012;6:E209–12.
28. Nakhjavani MK, Gharib H, Goellner JR, van Heerden JA. Metastasis to the thyroid gland. A report of 43 cases. *Cancer*. 1997;79:574–8.
29. Kim TY, Kim WB, Gong G, Hong SJ, Shong YK. Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. *Clin Endocrinol (Oxf)*. 2005;62:236–41.
30. Wood K, Vini L, Harmer C. Metastases to the thyroid gland: the Royal Marsden experience. *Eur J Surg Oncol*. 2004;30:583–8.
31. Cichon S, Anielski R, Konturek A, Barczynski M, Cichon W. Metastases to the thyroid gland: seventeen cases operated on in a single clinical center. *Langenbecks Arch Surg*. 2006;391:581–7.
32. Czech JM, Lichter TR, Carney JA, van Heerden JA. Neoplasms metastatic to the thyroid gland. *Surg Gynecol Obstet*. 1982;155:503–5.
33. Ericsson M, Björklund A, Cederquist E, Ingemansson S, Akerman M. Surgical treatment of metastatic disease in the thyroid gland. *J Surg Oncol*. 1981;17:15–23.
34. Elliott RH Jr, Frantz VK. Metastatic carcinoma masquerading as primary thyroid cancer: a report of authors' 14 cases. *Ann Surg*. 1960;151:551–61.
35. Harcourt-Webster JN. Secondary neoplasm of the thyroid presenting as a goitre. *J Clin Pathol*. 1965;18:282–7.
36. Brady LW, O'Neill EA, Farber SH. Unusual sites of metastases. *Semin Oncol*. 1977;4:59–64.
37. Ivy HK. Cancer metastatic to the thyroid: a diagnostic problem. *Mayo Clin Proc*. 1984;59:856–9.
38. Lam KY, Lo CY. Metastatic tumors of the thyroid gland: a study of 79 cases in Chinese patients. *Arch Pathol Lab Med*. 1998;122:37–41.
39. Gerges AS, Shehata SR, Gouda IA. Metastasis to the thyroid gland; unusual site of metastasis. *J Egypt Natl Canc Inst*. 2006;18:67–72.
40. Chen H, Nicol TL, Udelsman R. Clinically significant, isolated metastatic disease to the thyroid gland. *World J Surg*. 1999;23:177–80.
41. Russell JO, Yan K, Burkey B, Scharpf J. Nonthyroid metastasis to the thyroid gland: case series and review with observations by primary pathology. *Otolaryngol Head Neck Surg*. 2016 Jun 21; p 0194599816655783.
42. Mayo CW, Schlicke CP. Exogenous tumors of the thyroid gland. *Am J Pathol*. 1941;17:283–8.
43. Wychulis AR, Beahrs OH, Woolner LB. Metastasis of carcinoma to the thyroid gland. *Ann Surg*. 1964;160:169–77.
44. Pillay SP, Angorn IB, Baker LW. Tumour metastasis to the thyroid gland. *S Afr Med J*. 1977;51:509–12.
45. Chacho MS, Greenebaum E, Moussouris HF, Schreiber K, Koss LG. Value of aspiration cytology of the thyroid in metastatic disease. *Acta Cytol*. 1987;31:705–12.
46. Smith SA, Gharib H, Goellner JR. Fine-needle aspiration. Usefulness for diagnosis and management of metastatic carcinoma to the thyroid. *Arch Intern Med*. 1987;147:311–2.
47. Michelow PM, Leiman G. Metastases to the thyroid gland: diagnosis by aspiration cytology. *Diagn Cytopathol*. 1995;13:209–13.
48. Dequanter D, Lothaire P, Larsimont D, de Saint-Aubain de Sommerhausen N, Andry G. [Intrathyroid metastasis: 11 cases]. *Ann Endocrinol (Paris)*. 2004;65:205–8.
49. Mirallie E, Rigaud J, Mathonnet M, et al. Management and prognosis of metastases to the thyroid gland. *J Am Coll Surg*. 2005;200:203–7.
50. Choi SH, Baek JH, Ha EJ, et al. Diagnosis of metastasis to the thyroid gland: comparison of core-needle biopsy and fine-needle aspiration. *Otolaryngol Head Neck Surg*. 2016;154:618–25.
51. Berge T, Lundberg S. Cancer in Malmo, 1958–1969. An autopsy study. *Acta Pathol Microbiol Scand Suppl*. 1977;(260):1–235.

52. Papi G, Fadda G, Corsello SM, et al. Metastases to the thyroid gland: prevalence, clinicopathological aspects and prognosis: a 10-year experience. *Clin Endocrinol (Oxf)*. 2007;66:565–71.
53. Shimaoka K. Thyrotoxicosis due to metastatic involvement of the thyroid. *Arch Intern Med*. 1980;140:284–5.
54. Peparini N, Di Matteo FM, Maturio A, Marzullo A, Campana FP. Unusual metastasis of gastrointestinal stromal tumor misdiagnosed as anaplastic thyroid carcinoma. *Int J Surg*. 2008;6:415–7.
55. Cozzolino I, Malapelle U, Carlomagno C, Palombini L, Troncone G. Metastasis of colon cancer to the thyroid gland: a case diagnosed on fine-needle aspirate by a combined cytological, immunocytochemical, and molecular approach. *Diagn Cytopathol*. 2010;38:932–5.
56. Mattavelli F, Collini P, Gervasoni C, et al. Double, metachronous thyroid metastases of colon cancer. *Tumori*. 2006;92:249–51.
57. Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. *Mayo Clin Proc*. 2014;89:504–19.
58. Burt A, Goudie RB. Diagnosis of primary thyroid carcinoma by immunohistological demonstration of thyroglobulin. *Histopathology*. 1979;3:279–86.
59. Katsuya Y, Yoshida A, Watanabe S, Tsuta K. Tumour-to-tumour metastasis from papillary thyroid carcinoma with *BRAF* mutation to lung adenocarcinoma with *EGFR* mutation: the utility of mutation-specific antibodies. *Histopathology*. 2015;67:262–6.
60. Kumamoto K, Utsumi Y, Sugano K, Hoshino M, Suzuki S, Takenoshita S. Colon carcinoma metastasis to the thyroid gland: report of a case with a review of the literature. *Tumori*. 2006;92:252–6.
61. Hurlimann J, Gardiol D, Scazziga B. Immunohistology of anaplastic thyroid carcinoma. A study of 43 cases. *Histopathology*. 1987;11:567–80.
62. Lin JD, Weng HF, Ho YS. Clinical and pathological characteristics of secondary thyroid cancer. *Thyroid*. 1998;8:149–53.
63. Iesalnieks I, Winter H, Bareck E, et al. Thyroid metastases of renal cell carcinoma: clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients' survival. *Thyroid*. 2008;18:615–24.
64. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. *J Clin Oncol*. 1998;16:2261–6.
65. Ishikawa M, Hirano S, Tsuji T, Ito J. Management of metastasis to the thyroid gland. *Auris Nasus Larynx*. 2011;38:426–30.
66. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. *J Urol*. 1986;136:376–9.
67. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. *J Clin Oncol*. 1994;12:206–12.
68. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. *CA Cancer J Clin*. 2012;62:283–98.
69. Thelen A, Jonas S, Benckert C, et al. Liver resection for metastases from renal cell carcinoma. *World J Surg*. 2007;31:802–7.
70. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol*. 2015;67:913–24.
71. Salah S, Tanvetyanon T, Abbasi S. Metastectomy for extracranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. *Lung Cancer*. 2012;75:9–14.
72. Arriagada R, Rutqvist LE, Johansson H, Kramar A, Rotstein S. Predicting distant dissemination in patients with early breast cancer. *Acta Oncol*. 2008;47:1113–21.
73. Liu YP, Tiu CM, Chou YH, et al. Thyroid metastasis from breast cancer presenting with diffuse microcalcifications on sonography: a case report. *J Clin Ultrasound*. 2014;42:430–2.
74. Lievre A, Leboulleux S, Boige V, et al. Thyroid metastases from colorectal cancer: the Institut Gustave Roussy experience. *Eur J Cancer*. 2006;42:1756–9.
75. Kung B, Aftab S, Wood M, Rosen D. Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. *Ear Nose Throat J*. 2009;88:E7.
76. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. *Int J Radiat Oncol Biol Phys*. 1987;13:665–72.
77. Silverberg SG, Vidone RA. Carcinoma of the thyroid in surgical and postmortem material. Analysis of 300 cases at autopsy and literature review. *Ann Surg*. 1966;164:291–9.